New pill shows promise for rare hormone disorder in Long-Term trial
NCT ID NCT06712823
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study is testing the long-term safety and effectiveness of a daily pill called atumelnant for people with classic congenital adrenal hyperplasia (CAH). The drug works by blocking a hormone receptor to help control excess androgen production. Researchers will monitor 150 participants who previously completed a Crinetics study to see if atumelnant can reduce the need for steroids and improve hormone levels over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atumelnant (CRN04894)
- What this could lead to
- If successful, this could provide a new treatment option to better control hormone levels and reduce steroid use in people with classic congenital adrenal hyperplasia.
- What could go wrong
- This is an extension study, so it builds on earlier results. It is still in Phase 2, meaning it is not yet proven to be safe and effective long-term. Side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Crinetics Study Site
ACTIVE_NOT_RECRUITINGMorehead City, North Carolina, 28557, United States
-
Crinetics Study Site
ACTIVE_NOT_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Crinetics Study Site
RECRUITINGCórdoba, Córdoba Province, 5000, Argentina
-
Crinetics Study Site
RECRUITINGCuritiba, Paraná, 80030-110, Brazil
-
Crinetics Study Site
RECRUITINGPorto Alegre, Rio Grande do Sul, 90410-000, Brazil
-
Crinetics Study Site
RECRUITINGBotucatu, São Paulo, 18618-686, Brazil
-
Crinetics Study Site
RECRUITINGRio de Janeiro, 20231-092, Brazil
-
Crinetics Study Site
RECRUITINGSão Paulo, 05403-000, Brazil
-
Crinetics Study Site
RECRUITINGMunich, Bavaria, 80336, Germany
-
Crinetics Study Site
RECRUITINGRoma, 00161, Italy
-
Crinetics Study Site
RECRUITINGBirmingham, CV22DX, United Kingdom
-
Crinetics Study Site
RECRUITINGLondon, NW1 2BU, United Kingdom
-
Crinetics Study Site, Minneapolis, Minnesota 55454
ACTIVE_NOT_RECRUITINGMinneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple saliva test replace blood draws for hormone monitoring?
- New program aims to smooth healthcare transition for teens with rare hormone disorder
- New hope for CAH: drug may slash steroid use
- New hope for toddlers with rare hormone disorder?
- Italian study checks how well newborn screening detects rare hormone disorder
- New hormone treatment shows promise for rare adrenal disorder